Literature DB >> 11927505

Human leukocyte antigen class I alleles and cervical neoplasia: no heterozygote advantage.

Sophia S Wang1, Allan Hildesheim, Xiaojiang Gao, Mark Schiffman, Rolando Herrero, M Concepcion Bratti, Mark E Sherman, Willard A Barnes, Mitchell D Greenberg, Larry McGowan, Rodrigue Mortel, Peter E Schwartz, Richard J Zaino, Andrew G Glass, Robert D Burk, Peter Karacki, Mary Carrington.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 11927505

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN： 1055-9965            Impact factor:   4.254


× No keyword cloud information.
  4 in total

1.  HLA-Cw group 1 ligands for KIR increase susceptibility to invasive cervical cancer.

Authors:  Maureen P Martin; Ingrid B Borecki; Zhengyan Zhang; Loan Nguyen; Duanduan Ma; Xiaojiang Gao; Ying Qi; Mary Carrington; Janet S Rader
Journal:  Immunogenetics       Date:  2010-09-21       Impact factor: 2.846

2.  HLA-A alleles and the risk of cervical squamous cell carcinoma in Japanese women.

Authors:  Satoyo Hosono; Takakazu Kawase; Keitaro Matsuo; Miki Watanabe; Hiroaki Kajiyama; Kaoru Hirose; Takeshi Suzuki; Kumiko Kidokoro; Hidemi Ito; Toru Nakanishi; Yasushi Yatabe; Nobuyuki Hamajima; Fumitaka Kikkawa; Kazuo Tajima; Hideo Tanaka
Journal:  J Epidemiol       Date:  2010-05-22       Impact factor: 3.211

3.  Human Leukocyte Antigen Class I and II Alleles and Cervical Adenocarcinoma.

Authors:  Mahboobeh Safaeian; Lisa G Johnson; Kai Yu; Sophia S Wang; Patti E Gravitt; John A Hansen; Mary Carrington; Stephen M Schwartz; Xiaojiang Gao; Allan Hildesheim; Margaret M Madeleine
Journal:  Front Oncol       Date:  2014-06-19       Impact factor: 6.244

4.  Human Leukocyte Antigen Class I and Class II Polymorphisms and Serum Cytokine Profiles in Cervical Cancer.

Authors:  Larissa Bahls; Roger Yamakawa; Karina Zanão; Daniela Alfieri; Tamires Flauzino; Francieli Delongui; André de Abreu; Raquel Souza; Fabrícia Gimenes; Edna Reiche; Sueli Borelli; Marcia Consolaro
Journal:  Int J Mol Sci       Date:  2017-08-31       Impact factor: 5.923
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.